As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.
23 Analysts have issued a Immunovant Inc forecast:
23 Analysts have issued a Immunovant Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -486 -486 |
38%
38%
|
|
| EBIT (Operating Income) EBIT | -487 -487 |
38%
38%
|
|
| Net Profit | -465 -465 |
44%
44%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Eric Venker |
| Employees | 207 |
| Founded | 2018 |
| Website | immunovant.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


